Delcath Systems, Inc. (DCTH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 4 | 3 | 2 | 37 | 85 | 95 | 106 |
| Operating profit | $m | 1 | -2 | ||||||
| Net profit | $m | -24 | -26 | -37 | -48 | -26 | 3 | 1 | -7 |
| EPS reported | $ | 0.07 | 0.01 | ||||||
| Operating cashflow per share | $ | 0.63 | 0.55 | ||||||
| Capex per share | $ | 0.04 | 0.06 | ||||||
| FCF per share | $ | 0.59 | 0.49 | ||||||
| Free cash flow | $m | 21 | 18 | ||||||
| Net debt | $m | -91 | -96 | ||||||
| Book value equity | $m | 111 | 121 | ||||||
| Book value per share | $ | 2.79 | 3.05 | ||||||
| Number of shares | m | 39.92 | 39.76 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 144.29 | - | ||||||
| P/B LTM | x | 3.25 | 2.99 | ||||||
| P/S LTM | x | 4.24 | 3.79 | ||||||
| P/FCF LTM | x | 17.25 | 20.67 | ||||||
| EV/EBITDA LTM | x | 82.74 | 188.36 | ||||||
| EV/Sales LTM | x | 3.75 | 5.49 | ||||||
| Earnings Yield LTM | % | +0.69% | +0.09% | ||||||
| FCF Yield | % | +5.80% | +4.84% | ||||||
| Quality | |||||||||
| ROE | % | +2.43% | +0.46% | ||||||
| ROIC | % | +0.45% | -0.60% | ||||||
| Operating margin | % | +0.77% | -1.90% | ||||||
| Gross margin | % | +86.16% | +87.05% | ||||||
| FCF/Sales | % | +24.60% | +18.35% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +129.08% | +156.47% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 22.40 | 7.11 | ||||||
| Net Debt/EBITDA | x | -11.02 | -26.58 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.82 | -0.79 | ||||||
| Gross debt/equity | x | 0.01 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free